Grants and Contributions:
Title:
Lipid nanoparticle drugs for immunomodulatory therapy of autoimmune/inflammatory disease
Agreement Number:
940510
Agreement Value:
$193,456.00
Agreement Date:
Dec 16, 2019 - Mar 31, 2021
Description:
This project aims to develop effective immunomodulatory formulations to induce immune tolerance as a therapeutic strategy for autoimmune and inflammatory diseases.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6S 1C3
Reference Number:
172-2019-2020-Q4-940510
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
824601991
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 90 days.
Amendment Date
Sep 22, 2020
Recipient's Legal Name:
Integrated Nanotherapeutics Inc.
Federal Riding Name:
Vancouver Quadra
Federal Riding Number:
59039
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: